ARVINAS INC. - COMMON

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

24 يونيو 2024 15:37:13 بحسب Nasdaq GlobeNewswire

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

21 يونيو 2024 06:00:51 بحسب Nasdaq GlobeNewswire

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

17 يونيو 2024 06:00:03 بحسب Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

03 يونيو 2024 15:30:00 بحسب Nasdaq GlobeNewswire

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

23 مايو 2024 16:00:15 بحسب Nasdaq GlobeNewswire

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

16 مايو 2024 05:00:45 بحسب Nasdaq GlobeNewswire

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

09 مايو 2024 15:42:04 بحسب Nasdaq GlobeNewswire

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

07 مايو 2024 06:00:11 بحسب Nasdaq GlobeNewswire

Arvinas to Present at Upcoming Investor Conferences

02 مايو 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

24 أبريل 2024 15:30:38 بحسب Nasdaq GlobeNewswire

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

11 أبريل 2024 06:00:49 بحسب Nasdaq GlobeNewswire

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

18 مارس 2024 15:40:46 بحسب Nasdaq GlobeNewswire

Arvinas to Participate in Upcoming Investor Conferences

04 مارس 2024 06:00:04 بحسب Nasdaq GlobeNewswire

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

27 فبراير 2024 06:00:07 بحسب Nasdaq GlobeNewswire

Arvinas Announces Chief Financial Officer Transition

20 فبراير 2024 15:05:04 بحسب Nasdaq GlobeNewswire

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

20 فبراير 2024 06:00:44 بحسب Nasdaq GlobeNewswire

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

06 فبراير 2024 05:45:00 بحسب Nasdaq GlobeNewswire

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

01 فبراير 2024 15:30:20 بحسب Nasdaq GlobeNewswire

Arvinas Appoints Jared Freedberg as General Counsel

16 يناير 2024 16:01:06 بحسب Nasdaq GlobeNewswire

Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program

05 ديسمبر 2023 21:52:59 بحسب Nasdaq GlobeNewswire